Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

-based irreversible inhibitor of the 20S proteasome. This second-generation proteasome inhibitor (PI) is structurally and mechanistically different to the dipeptide boronic acid PI, bortezomib. Compared

  • 22 views
  • 21 Jan, 2021
  • 1 location
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 20 Jun, 2021
  • 37 locations
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. …

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody.

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti

  • 0 views
  • 26 Jan, 2021
  • 5 locations
A Safety PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

and refractory multiple myeloma (RRMM). RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be

immunotherapeutic agent
neutrophil count
measurable disease
proteasome inhibitor
bone marrow procedure
  • 161 views
  • 26 Jan, 2021
  • 18 locations
Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma

Drug (IMiD) and a Proteasome Inhibitor (PI) (regardless of the number of prior lines of therapy), or have received at least 3 prior lines of therapy including an IMiD and a PI. Patients will

dexamethasone
refractory multiple myeloma
melphalan
progressive disease
  • 0 views
  • 02 Jun, 2021
  • 32 locations
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the

acute leukemia
daunorubicin
pegaspargase
residual tumor
etoposide
  • 562 views
  • 26 Jan, 2021
  • 168 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), and the proteasome inhibitor bortezomib for those lacking targetable lesions. To improve overall treatment outcome of T acute

dexamethasone
daunorubicin
intrathecal chemotherapy
cancer
pegaspargase
  • 230 views
  • 29 Jan, 2021
  • 7 locations
A Study of WVT078 in Patients With Multiple Myeloma (MM)

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

refractory multiple myeloma
proteasome inhibitor
immunomodulatory imide drug
  • 8 views
  • 12 Jun, 2021
  • 12 locations
A Study Comparing JNJ-68284528 a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA) Versus Pomalidomide Bortezomib and Dexamethasone (PVd) or Daratumumab Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

The purpose of this study is to compare the efficacy of JNJ-68284528 with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

neutrophil count
measurable disease
proteasome inhibitor
filgrastim
lenalidomide
  • 161 views
  • 04 Jun, 2021
  • 105 locations